Aby wyświetlić tę treść, wymagana jest subskrypcja JoVE. Zaloguj się lub rozpocznij bezpłatny okres próbny.
Method Article
For some patients, the only option for fertility preservation is cryopreservation of ovarian tissue. Unfortunately, delayed revascularization undermines follicular viability. Here, we present a protocol to co-transplant human ovarian tissue with endothelial cells for utilization as a cell-based strategy combining accelerated perfusion with a direct paracrine delivery of bioactive molecules.
Infertility is a frequent side effect of chemotherapy and/or radiotherapy and for some patients, cryopreservation of oocytes or embryos is not an option. As an alternative, an increasing number of these patients are choosing to cryopreserve ovarian tissue for autograft following recovery and remission. Despite improvements in outcomes among patients undergoing auto-transplantation of cryopreserved ovarian tissue, efficient revascularization of grafted tissue remains a major obstacle. To mitigate ischemia and thus improve outcomes in patients undergoing auto-transplantation, we developed a vascular cell-based strategy for accelerating perfusion of ovarian tissue. We describe a method for co-transplantation of exogenous endothelial cells (ExECs) with cryopreserved ovarian tissue in a mouse xenograft model. We extend this approach to employ ExECs that have been engineered to constitutively express Anti-Mullerian hormone (AMH), thus enabling sustained paracrine signaling input to ovarian grafts. Co-transplantation with ExECs increased follicular volume and improved antral follicle development, and AMH-expressing ExECs promoted retention of quiescent primordial follicles. This combined strategy may be a useful tool for mitigating ischemia and modulating follicular activation in the context of fertility preservation and/or infertility at large.
Cancer remains among the leading causes of death in the developed world, yet decades of research have yielded significant progress for most types of cancer, and in some cases nearly doubled survival rates1. Unfortunately, chemotherapeutic agents are often gonadotoxic, depleting the reserve of primordial follicles in ovaries and reducing fertility2. This growing population can benefit from various methods of fertility preservation including oocyte and/or embryo cryopreservation, however, patients requiring prompt initiation of cancer therapy and pre-pubertal patients are ineligible for these options. As an alternative, some patients have chosen to cryopreserve ovarian tissue before undertaking their therapeutic regimen, and upon recovery and remission, auto-transplanting tissue to restore fertility3. Yet, to date, graft survival and follicular output following auto-transplantation remain relatively low4, mainly due to tissue ischemia and hypoxia5,6,7. Despite numerous efforts to improve the viability of ovarian cortical grafts using anti-oxidants8,9, pro-angiogenic cytokines10,11,12,13, or mechanical manipulations14, graft ischemia in a 5 to 7 day window post-transplant undermines the viability and survival of the graft7. To address this, we developed a cell-based strategy to facilitate anastomosis of host and graft vessels and thus hasten reperfusion of ovarian tissue.
In addition to the ischemic insult to grafted ovarian tissue in the post-transplant window, the disruption of inter-follicular signaling may contribute to depletion of the pool15,16. Because exogenous endothelial cells (ExECs) contribute to stable and functioning vessels in the periphery of the graft, they present a unique opportunity to convey a defined molecular input to transplanted tissue. As a proof of principle, ExECs were engineered to express super-physiological levels of Anti-Mullerian hormone (AMH), a member of the transforming growth factor beta (TGFβ) superfamily that has been shown to restrict follicular growth17. Comparison of follicular distribution in grafts co-transplanted with control and AMH-expressing cells verifies the biological activity and potency of engineered exECs.
In summary, by improving graft viability and suppressing premature mobilization of the follicular pool, this approach can increase the productivity of auto-transplanted ovarian tissue in patients undergoing fertility preservation. Moreover, the ExEC-based platform enables experimental interrogation of molecular regulators that have been implicated in follicular development.
All procedures involving animal subjects have been approved by the Institutional Animal Care and Use Committee (IACUC) at Weill Cornell Medical College. All xenotransplantation experiments using ovarian tissue were performed in accordance with relevant guidelines and regulations. Human ovarian tissue was collected from patients scheduled for chemotherapy or radiotherapy for cancer treatment or prior bone marrow transplantation. The institutional review board (IRB) Committee of Weill Cornell Medical College approved the collection of tissue for potential autologous use, and upon the patient's informed consent a donation of up to 10% of their ovarian tissue for research use was performed.
1. Collection of Human Ovarian Tissue
NOTE: When an ovarian tissue is transported from a remote facility transit, time should not exceed 5 h18,19.
2. Processing the Procured Ovarian Tissue, Adapted from Schmidt et al.18
3. Ovarian Tissue Slow Freezing, Adapted from Newton et al. and Oktay et al.6,20
4. Preparations for the Surgeries (Bilateral Oophorectomy and Co-transplantation)
5. Ovarian Tissue Rapid Thawing
6. Encapsulation of the Ovarian Tissue
7. Bilateral Oophorectomy and Co-transplantation of Human Ovarian Tissue with Engineered Endothelial Cells to NSG Mice
NOTE: Ten to fourteen-week-old female NSG mice21 were used (Jackson Labs).
To determine whether co-transplantation of ExECs provides a benefit to patients' tissue, thawed ovarian cortical strips were divided into equal sized pieces and engrafted bilaterally into immuno-compromised, NOD scid gamma (NSG), mice. With one side embedded in a fibrin clot alone (no ECs) and the other containing ExECs (Figure 1a), each mouse served as its own control. ExECs were obtained via isolation of primary endothelium from human umbilical cords an...
Here we demonstrate that co-transplantation of exECs provides a significant benefit to ovarian tissue viability and function following xenograft in mice. Standards for clinical application of ovarian tissue auto-transplantation for fertility preservation have not been set and the optimal parameters (size, transplantation site, duration of graft, etc.)32,33,34 for enhanced recovery of the follicular pool remain undefined...
Michael Ginsberg is an employee of Angiocrine Biosciences, Inc., San Diego, CA, 92130, United States, that isolated, transfected with E4-ORF- 1 and labeled the endothelial cells we used.
Omar Alexander Man for the illustrations.
L.M. was supported by a Pilot Award from the Cornell Clinical and Translational Science Center and an ASRM research grant.
The authors would like to thank James lab members for critical reading of the manuscript.
Name | Company | Catalog Number | Comments |
Leibovitz’s L-15 medium | Gibco | 11415064 | |
Antibiotic-Antimycotic | Gibco | 15240062 | Anti-Anti X100 |
Sucrose | Sigma | S 1888 | |
Fibrinogen | Sigma | F 8630 | from bovine plasma |
Thrombin | Sigma | T 1063 | from human plasma |
DMSO | Sigma | D 2650 | |
DMEM | Gibco | 12491015 | |
Enzyme Cell Detachment Medium | Invitrogen | 00-4555-56 | Accutase |
Plastic paraffin film | Bemis NA | Parafilm M | |
Surgical paper tape 2.5 cm | 3M | 1530-1 | Micropore |
Surgical Paper tape 1.25 cm | 3M | 1530-0 | Micropore |
Perforated plastic Surgical tape 1.25 cm | 3M | 1527-0 | Transpore |
Monofilament Absorbable Suture | Covidien | UM-203 | Biosyn |
Braided Absorbable Suture | Covidien | GL-889 | Polysorb |
Povidone-iodine Solution USP 10% | Purdue Products | 67618-153-01 | Betadine Solution Swab Stick |
Cryoviales | Nunc | 377267 | CryoTube |
sterile ocular lubricant | Dechra | 17033-211-38 | Puralube |
1.7 ml micro-centrifuge tube | Denville | C-2172 | Eppendorf |
Anasthesia system | VetEquip | V-1 table top system with scavenging | |
Endothelial cells | Angiocrine Biosciences, Inc., San Diego, CA, USA | Isolated, transfected with E4-ORF- 1 and labeled endothelial cells | |
Trichrome stain | Sigma | HT15-1kt | Trichrome Stain (Masson) Kit |
Isolectin | Invitrogen | I32450 | isolectin GS-IB4 From Griffonia simplicifolia, Alexa Fluor™ 647 Conjugate |
Zapytaj o uprawnienia na użycie tekstu lub obrazów z tego artykułu JoVE
Zapytaj o uprawnieniaThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. Wszelkie prawa zastrzeżone